Expert Review,case study

The relationship between semaglutide, a widely used glucagon-like peptide-1 (GLP-1) receptor agonist, and mental health, particularly depression, is a topic of growing interest and scientific inquiry. While semaglutide has demonstrated significant efficacy in managing type 2 diabetes and promoting weight loss, a number of case reports and studies have begun to explore potential associations with depressive symptoms and other psychiatric effects. This article delves into the available evidence, focusing on case report depression semaglutide findings, semaglutide-associated depression, and the broader implications for patient care.

Understanding Semaglutide and its Potential Impact on Mood

Semaglutide, marketed under brand names like Ozempic and Wegovy, mimics the action of the GLP-1 hormone. This mechanism aids in regulating blood sugar levels and promotes satiety, contributing to its therapeutic benefits. However, the intricate interplay between the gut-brain axis and hormonal regulation means that medications affecting these systems can sometimes have unforeseen effects on mood.

Recent research, including a significant study by Kornelius et al. (2024), has indicated a potential link between GLP-1 receptor agonist (GLP-1 RA) treatment and an increased risk of psychiatric disorders. This finding, which showed a 98% increased risk of any psychiatric disorders, has prompted further investigation into the specific nature of these associations.

Examining Case Reports of Semaglutide-Associated Depression

Several case reports have highlighted instances where patients have experienced depressive symptoms during or after treatment with semaglutide. For example, a notable report by Li et al. (2023) details two cases of semaglutide-associated depression. In one of these cases, a middle-aged man with no prior history of depression developed depressive symptoms while on the medication. These reports underscore the importance of recognizing semaglutide-associated depression as a potential adverse effect.

Another case report published in 2025 by Stojkovska et al. emphasizes the need for vigilant monitoring of depression and anxiety symptoms, as well as the potential for suicidal ideation, in patients prescribed semaglutide. Similarly, a case report presented at the APA 2024 conference described a 42-year-old female who exhibited suicidal ideation after initiating semaglutide. These cases collectively contribute to a growing body of evidence suggesting a possible, albeit not fully understood, connection.

It is crucial to note that not all research points to a negative association. A post-hoc analysis discussed by Thomas A. Wadden, PhD, in September 2024, suggested that taking semaglutide for weight management does not increase the risk of depression or suicidal thoughts in individuals without a history of psychiatric conditions. Furthermore, a study by Nishida et al. (2025) indicated that among participants with no history of major psychopathology, there is no association between semaglutide and depression and suicidality. This suggests that pre-existing mental health conditions might play a role in the emergence of these symptoms.

Exploring the Nuances: Worsening Symptoms and Specific Presentations

Beyond new-onset depression, some case reports describe a worsening depression in individuals with a prior history of mood disorders. A case report highlighted in Reactions Weekly in August 2025 discussed semaglutide-related depressive disorders, pointing to the potential for exacerbation of existing conditions. One particularly interesting case report from Savoldy (2026) presented the first documented semaglutide-associated exacerbation of PNEA (psychogenic non-epileptic attacks) in a patient with previously stable functional status, further illustrating the complex psychiatric effects that can manifest.

Additionally, research is investigating the broader spectrum of psychiatric adverse events. A pharmacovigilance analysis by Tobaiqy et al. (2024) identified psychiatric adverse events as a potential concern with semaglutide, liraglutide, and tirzepatide, although their true risk remains unclear. A case study in February 2025 detailed a 77-year-old woman with bipolar disorder who experienced transient euphoria following semaglutide use for obesity, demonstrating that mood alterations can manifest in various ways.

The Importance of Further Research and Patient Monitoring

While the emerging evidence is compelling, it is important to emphasize that the exact causal relationship between semaglutide and depression is still under investigation. The U.S. Food and Drug Administration (FDA) has stated that no psychiatric adverse effect associated with semaglutide has been reported in some contexts, highlighting ongoing debate and data analysis. However, post-marketing reports have linked semaglutide to depression and suicidal ideation, prompting regulatory scrutiny.

The study by Taipale et al. (2026) is notable for suggesting that people using GLP-1 RAs were *less* likely to have worsening mental illness, presenting a